NCT02304432View on ClinicalTrials.gov

Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 27, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

July 31, 2017

Conditions
SchizophreniaBipolar Disorder
Interventions
DRUG

D-cycloserine

Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.

DRUG

DCS or placebo

Double-blind placebo-controlled exposures to DCS or placebo x 6 weeks. One participant received exposure to DCS x 6 weeks and then received placebo dosing x 6 weeks. The other participant received exposure to placebo dosing x 6 weeks and then DCS x 6 weeks.

DRUG

D-cycloserine

Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.

All Listed Sponsors
collaborator

University of Minnesota

OTHER

lead

Mclean Hospital

OTHER

NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine | Biotech Hunter | Biotech Hunter